Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 14.57
ABMD's Cash-to-Debt is ranked higher than
63% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ABMD: 14.57 )
Ranked among companies with meaningful Cash-to-Debt only.
ABMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.95  Med: No Debt Max: No Debt
Current: 14.57
Equity-to-Asset 0.83
ABMD's Equity-to-Asset is ranked higher than
85% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABMD: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
ABMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.85 Max: 0.95
Current: 0.83
0.52
0.95
Interest Coverage N/A
ABMD's Interest Coverage is ranked higher than
73% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. ABMD: N/A )
Ranked among companies with meaningful Interest Coverage only.
ABMD' s Interest Coverage Range Over the Past 10 Years
Min: 506.67  Med: No Debt Max: No Debt
Current: N/A
Piotroski F-Score: 4
Altman Z-Score: 40.98
Beneish M-Score: -2.75
WACC vs ROIC
-0.61%
28.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 19.53
ABMD's Operating Margin % is ranked higher than
88% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. ABMD: 19.53 )
Ranked among companies with meaningful Operating Margin % only.
ABMD' s Operating Margin % Range Over the Past 10 Years
Min: -61.9  Med: -4.93 Max: 19.76
Current: 19.53
-61.9
19.76
Net Margin % 11.63
ABMD's Net Margin % is ranked higher than
80% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. ABMD: 11.63 )
Ranked among companies with meaningful Net Margin % only.
ABMD' s Net Margin % Range Over the Past 10 Years
Min: -69.44  Med: -5.22 Max: 49.36
Current: 11.63
-69.44
49.36
ROE % 12.64
ABMD's ROE % is ranked higher than
77% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ABMD: 12.64 )
Ranked among companies with meaningful ROE % only.
ABMD' s ROE % Range Over the Past 10 Years
Min: -37.95  Med: -4.88 Max: 49.44
Current: 12.64
-37.95
49.44
ROA % 10.86
ABMD's ROA % is ranked higher than
86% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. ABMD: 10.86 )
Ranked among companies with meaningful ROA % only.
ABMD' s ROA % Range Over the Past 10 Years
Min: -32.2  Med: -3.98 Max: 41.81
Current: 10.86
-32.2
41.81
ROC (Joel Greenblatt) % 113.32
ABMD's ROC (Joel Greenblatt) % is ranked higher than
95% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. ABMD: 113.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -220.87  Med: -46.22 Max: 171.62
Current: 113.32
-220.87
171.62
3-Year Revenue Growth Rate 24.00
ABMD's 3-Year Revenue Growth Rate is ranked higher than
91% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ABMD: 24.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.6  Med: 11.8 Max: 51.9
Current: 24
-30.6
51.9
3-Year EBITDA Growth Rate 48.10
ABMD's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. ABMD: 48.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56  Med: 11 Max: 136.2
Current: 48.1
-56
136.2
3-Year EPS without NRI Growth Rate 31.90
ABMD's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ABMD: 31.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8  Med: 18.6 Max: 304.6
Current: 31.9
-57.8
304.6
GuruFocus has detected 3 Warning Signs with Abiomed Inc $ABMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABMD's 10-Y Financials

Financials (Next Earnings Date: 2017-05-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABMD Guru Trades in Q1 2016

Columbia Wanger 137,717 sh (New)
Jim Simons 287,100 sh (+152.51%)
Paul Tudor Jones 2,600 sh (unchged)
PRIMECAP Management 5,535,290 sh (-2.15%)
» More
Q2 2016

ABMD Guru Trades in Q2 2016

Joel Greenblatt 3,013 sh (New)
Columbia Wanger 388,958 sh (+182.43%)
Jim Simons 621,723 sh (+116.55%)
Paul Tudor Jones Sold Out
PRIMECAP Management 5,006,490 sh (-9.55%)
» More
Q3 2016

ABMD Guru Trades in Q3 2016

Jim Simons 660,223 sh (+6.19%)
Joel Greenblatt Sold Out
PRIMECAP Management 4,708,590 sh (-5.95%)
Columbia Wanger 80,790 sh (-79.23%)
» More
Q4 2016

ABMD Guru Trades in Q4 2016

Steven Cohen 92,600 sh (New)
Chuck Royce 10,000 sh (New)
Columbia Wanger 311,535 sh (+285.61%)
PRIMECAP Management 4,676,630 sh (-0.68%)
Jim Simons 523,900 sh (-20.65%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:WILYY, NAS:MASI, OTCPK:CHEOY, OTCPK:SDMHF, NAS:NUVA, OTCPK:FSPKF, OTCPK:EKTAY, OTCPK:CNVVY, OTCPK:GGNDF, NAS:IART, NAS:WMGI, NYSE:GMED, NYSE:PEN, NYSE:VAR, NYSE:NVRO, NAS:LIVN, NAS:ZLTQ, NYSE:TFX, OTCPK:NHNKY, OTCPK:IOBCF » details
Traded in other countries:AIO.Germany,
Headquarter Location:USA
Abiomed Inc is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients.

Abiomed provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are primarily used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. They work by improving blood flow to coronary arteries or temporarily performing the pumping function of the heart. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

Top Ranked Articles about Abiomed Inc

Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts

Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts

DANVERS, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Massachusetts Governor Charlie Baker today joined Abiomed – a leading provider of breakthrough heart support and recovery technologies – for the grand opening of its newly expanded global headquarters in Danvers.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a85c5b1d-6799-4fc6-b6bb-40e104632b3a. With the expansion, Abiomed more than doubles the size of its headquarters from 60,000 square feet to 160,000 square feet adding new research and manufacturing capabilities, along with the new Heart Recovery Institute for clinical education – a cutting edge training facility.  It represents a more than $40 million investment in Massachusetts for education, manufacturing, and training. “With Massachusetts-based companies like Abiomed helping to lead the way, the Commonwealth continues to be a global leader in health care, innovation and technology,” said Governor Charlie Baker. “I am pleased to continue to witness the growth of a company that has invested in Massachusetts for more than 35 years and we look forward to continuing to work together to create jobs and develop the state’s innovation economy.” Abiomed broke ground on the construction in June 2015 and has since added more than 150 engineering and manufacturing jobs to the site. The company now has more than 400 employees in Massachusetts, over 700 in the United States, and globally is nearing 1,000. Abiomed is also expanding its capacity in Berlin and Aachen, Germany and Tokyo, Japan. “Today we recognize 35 years of dedication and hard work by all the people who made this possible – from employees, to customers, to patients, to investors,” said Abiomed President, Chairman and CEO Mike Minogue. “We celebrate our Patients First culture and this investment in our future. We are proud to add new clinical, engineering and manufacturing jobs in Massachusetts because it will ensure faster innovation, quality, and compliance. Our mission is to help recover hearts; now we have the manufacturing infrastructure to support enough patients to fill Fenway Park each year.” During the event, Abiomed also recognized two cardiac patients that benefited from the company’s lifesaving technology. Conference rooms were named in honor of milestone patients Rogelio Landin of Detroit, MI and Howard Gaynor of Hartford, CT. Robert Pasquariella, a patient treated with the Impella device from Everett, Mass., also attended the event with his son Bobby who was part of the construction team that worked on the expansion. Abiomed has been in Massachusetts since 1981, securing three FDA approvals and earning 264 patents with another 237 pending. The company recently announced that it has supported more than 50,000 patients in the U.S. with Impella®, the world’s smallest heart pump – which can help the heart rest, recover and in some cases, heal. Abiomed is the only company with FDA approval for heart recovery and the Impella is the only FDA-approved percutaneous hemodynamic support device approved safe and effective for the treatment of high risk patients, and patients with Acute Myocardial Infarction Cardiogenic Shock (AMICS). ABOUT IMPELLA HEART PUMPS The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com. FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
Media Contact
Laura Wareck
[email protected] | 978-660-9587
Adrienne Smith
[email protected] |781-277-1170

Read more...
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session

- Real-World Data Representing 15,259 Patients WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed’s (NASDAQ:ABMD) Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database documenting the real-world treatment of approximately 50,000 U.S. patients, with a subset of 15,259 Acute Myocardial Infarction Cardiogenic Shock (AMICS) patients. The Impella heart pump results indicate an association between the use of best practice protocols and improved survival and native heart recovery, as compared to inconsistent treatment or inexperienced hospitals. The Abiomed IQ Assurance Program is a real-world collection of clinical information derived from the treatment of patients with Impella devices since 2008. Trends in the observational IQ Database, combined with information from Abiomed’s Institutional Review Board (IRB)-approved cVAD Registry have helped identify best practices and protocols that are associated with improved survival and native heart recovery in hospitals using Impella devices. Best practice protocols include: Unloading the left ventricle of the heart (Door to Unload or DTU) with Impella before percutaneous coronary intervention (pre-PCI) in the setting of cardiogenic shockReducing the escalation of inotrope therapyUtilizing hemodynamic monitoring for escalation and weaning during supportExperienced physicians implanting Impella heart pumps Results from the IQ Database reveal that since the Impella line of heart pumps received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) in April 2016 for use in treating AMICS5, there has been an observed 14 percent relative improvement in survival as compared to the prior year. In 2016, there were 89,000 AMICS cases nationwide, and approximately 5,000 or about 6 percent, were treated with Impella heart pumps. This compares with approximately 35,600 or 40 percent treated with the intra-aortic balloon pump (IABP), even though randomized controlled trials show no hemodynamic augmentation or survival benefit for IABP patients in AMICS1,2. Though First 510(k) cleared in 1976 as a result of already being on the market, the IABP is not FDA approved as safe and effective for the AMICS indication. “The FDA deemed Impella devices safe and effective in the U.S. for cardiogenic shock less than one year ago, which has allowed us to collaborate with hospitals to expand education on hemodynamic science and share best practices to achieve native heart recovery across the country. We are pleased to see improvements of 14 percent this year and recognize the opportunity to further impact and improve the outcomes of thousands of patients with the lessons learned by the most advanced centers and physicians,” said Seth Bilazarian, MD, FACC, FSCAI, Chief Medical Officer, Abiomed. The data presented today also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), which is an unprecedented collaboration between five heart hospitals in Detroit. The presentation by study principal investigator William W. O’Neill, MD, FACC, FSCAI, Medical Director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit, highlighted the treatment of 37 patients utilizing these best practices and protocols derived from Abiomed’s IQ Assurance Program and our most experienced heart hospitals. Applying these systematic best practices, DCSI hospitals showed an increase in cardiogenic shock survival rates from 51 percent baseline to 84 percent, with 100 percent of survivors discharged home with their native heart. “These results validate earlier studies from the cVAD Registry that early circulatory support is critical for survival and heart recovery in cardiogenic shock,” said Dr. O’Neill. “We are proud of the positive results of our unprecedented collaboration. By sharing our best practice protocols, we remain committed to improving shock outcomes in Detroit and around the world.”  Impella SitesSurvivalSurvival
Improvement
(Absolute %)Survival
Improvement
(Relative %)Standardized
Protocols for Heart
RecoveryIQ Database n=15,5291,010 Hospitals58%7%14%NoTop 20% IQ n=3051158
Hospitals76%25%50%YesDetroit CSI
n=375 Hospital Systems84%33%65%Yes These new data support prior publications with percutaneous heart pumps (such as Impella) supporting cardiogenic shock patients published in JACC (National trends in the utilization of short-term mechanical circulatory support)3 and the Journal of Interventional Cardiology (Use of Impella 2.5 in Acute Myocardial Infarction complicated by Cardiogenic Shock)4 representing nearly 12,000 Medicare/insurance patients and 154 cVAD Registry patients respectively. The mission of the IQ Assurance Program is to improve real-world outcomes in Protected PCI and cardiogenic shock patients through training, education and utilization of clinical guidelines, protocols and best practices derived from observational quality assurance data (IQ), IRB approved registry data (cVAD) and IDE approved FDA studies. The points reflected specifically in the IQ Database, as compared to the IQ Program, which includes the cVAD Registry and FDA studies, are not statistically-powered or pre-specified, and no statistical conclusions can be drawn from the observational database. "Abiomed has invested to create the largest high-risk PCI6 and cardiogenic shock database of real-world evidence," said Michael R. Minogue, Abiomed President, Chairman and Chief Executive Officer. "We believe that by sharing our data-driven insights and clinical expertise, along with our 24x7 onsite and on-call support, we can help hospitals improve outcomes and reduce costs for the sickest patients in the system." ABOUT IMPELLA HEART PUMPS The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com. The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries. ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events. Wayangankar, S. et. al J Am Coll Cardiol. Int CATH-PCI Registry.Prondzinsky R. et al. Jn Critical Care Medicine IABP-SHOCK I 2010 – Clinicaltrial.gov # NCT00469248.Stretch, R. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol. 2014 Oct 7;64(14):1407-15. doi: 10.1016/j.jacc.2014.07.958.O’Neill, W. The current use of Impella 2.5 in Acute Myocardial Infarction complicated by Cardiogenic Shock: Results from the USpella Registry. J Interv Cardiol. 2014 Feb; 27(1): 1–11. doi: 10.1111/joic.12080.The data submitted to the FDA in support of the PMA included an analysis of 415 patients from the RECOVER 1 study and the U.S. Impella registry (cVAD Registry™), as well as an Impella literature review including 692 patients treated with Impella from 17 clinical studies. A safety analysis reviewed over 24,000 Impella treated patients using the FDA medical device reporting ("MDR") database, which draws from seven years of U.S. experience with Impella.
In addition, the Company also provided a benchmark analysis of Impella patients in the real-world Impella cVAD registry vs. these same patient groups in the Abiomed AB5000/BVS 5000 Registry. The Abiomed BVS 5000 product was the first ventricular assist device (VAD) ever approved by the FDA in 1991 based on 83 patient PMA study. In 2003, the AB5000 Ventricle received FDA approval and this also included a PMA study with 60 patients.
For this approval, the data source for this benchmark analysis was a registry ("AB/BVS Registry") that contained 2,152 patients that received the AB5000 and BVS 5000 devices, which were originally approved for heart recovery. The analysis examined by the FDA used 204 patients that received the AB5000 device for the same indications. This analysis demonstrated significantly better outcomes with Impella in these patients. The Company believes this is the most comprehensive review ever submitted to the FDA for circulatory support in the cardiogenic shock population.The Impella 2.5 heart pump received FDA PMA approval to treat certain elective and urgent high risk PCI patients in March of 2015. The Impella CP heart pump was subsequently approved to treat that patient population in December 2016. The data underpinning the FDA’s approval of the Impella 2.5 device included U.S. clinical trial data from the PROTECT I FDA safety study and the PROTECT II randomized clinical trial.
Additionally, the PMA submission for the Impella 2.5 device included an analysis of 637 high risk patients, from 49 separate centers, enrolled in the cVAD Registry (formerly known as the U.S. Impella registry), which now contains nearly 3,000 patient records and includes Institutional Review Board (IRB) approval, complete data monitoring and Clinical Events Committee adjudication. The Impella 2.5 PMA submission also included clinical and scientific supporting evidence from more than 215 publications, totaling 1,638 Impella 2.5 patients and incorporated a medical device reporting (MDR) analysis from 13,981 Impella 2.5 patients. In additional to this comprehensive data set, the FDA’s PMA approval for the Impella CP device included its consideration of 72 high risk Impella CP patients from the CVAD Registry, as well as an additional 637 Impella 2.5 device patients.
**For further information please contact:

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
[email protected]

Ingrid Goldberg
Director, Investor Relations
978-646-1590
[email protected]

Read more...
Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presentations

First Ever Scientific Presentation of Abiomed’s Impella® Quality (IQ) Assurance Program
DANVERS, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 10 presentations, including a late-breaking clinical research presentation, featuring the Impella® line of heart pumps, in addition to 17 poster presentations scheduled during the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 at the Walter E. Washington Convention Center in Washington, DC.
Abiomed is committed to improving outcomes in Protected PCI and cardiogenic shock through technology and innovation, excellence in education, clinical research, and appropriate and standardized use.  The following initiatives are planned for ACC:Featured Clinical Research: Outcomes for 15,259 Patients with Acute MI Cardiogenic Shock (AMICS) supported with Impella devices and early results from unprecedented collaboration in Detroit
On Sunday, March 19th at 2:00 PM, Dr. William O’Neill of Henry Ford Health System will present new data from the Impella Quality (IQ) Assurance Program, an initiative designed to improve outcomes in Protected PCI and cardiogenic shock. One component of the program is Abiomed's IQ Database, a real-world collection of clinical information derived from the treatment of patients with Impella devices over the past eight years. This observational data, combined with clinical data collected in the cVAD Registry and FDA pre- and post-market studies, is used to develop clinical protocols by highlighting the best practices associated with superior, real-world outcomes.Detroit Cardiogenic Shock Initiative (DCSI)
Leveraging best practices and protocols from Abiomed Impella Quality (IQ) Assurance Program, Dr. O’Neill will share early results and new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented partnership between five competitive hospital systems in metro Detroit with the goal of determining whether outcomes in cardiogenic shock can be improved with best practice protocols, including early use of Impella before PCI. These protocols are based on data derived from the IQ Database and top performing hospitals in Detroit.Abiomed Booth Activities
Abiomed's booth #2427 will feature daily demonstrations and opportunities for physicians to engage in hands-on simulations of the Impella platform with new simulator updates. Abiomed’s product specialists will discuss new technologies and innovations.Potential Live Cases Utilizing Impella Devices
Abiomed anticipates the potential broadcast of several live cases utilizing Impella devices from participating sites. Further details regarding these live cases will be announced the day of the scheduled procedures, as patient status is subject to change. The schedule for ACC symposia is included below. Additional Impella-related presentations and poster sessions are anticipated.  The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP)
Marriott Marquis, Marquis Ballroom, Salon 5, Level M2
Thursday, March 16 | 6:30-9:00 PM
Chairs:
Navin K. Kapur, MD
William L. Lombardi, MD
James M. McCabe, MD
Ajay J. Kirtane, MD, SMA Changing Approach to Percutaneous Hemodynamic Support: Decisions, Devices and Results
Marriott Marquis, Marquis Ballroom, Salon 5, Level M2
Saturday, March 18 | 6:15-7:45 AM
Faculty:
Navin K. Kapur, MD
William O’Neill, MD
Ajay Srivastava, MD
Eric Velazquez, MDABOUT IMPELLA HEART PUMPSThe Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries. ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
**For further information please contact:

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
[email protected]

Ingrid Goldberg
Director, Investor Relations
978-646-1590
[email protected]

Read more...
New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention

Circulation Research paper supports previously published randomized clinical trial data

DANVERS, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) can reduce the risk of acute kidney injury (AKI) even when those patients had preexisting kidney disease1 and low ejection fraction (EF). The new study builds upon earlier data from PROTECT II2, a randomized clinical trial, which found kidney injury rates were numerically lower when more contrast was used during HRPCI, and adds to the growing body of evidence of the benefits of hemodynamic support with Impella during HRPCI.
For the new retrospective, single-center study, investigators analyzed the procedure and clinical outcomes of 230 patients with an EF of 35 percent or less before undergoing HRPCI. Half of the patients studied were supported with Impella 2.5 during their procedure, and were compared with a matched-controlled cohort of 115 patients undergoing HRPCI without Impella. In the study, Impella-supported patients were more likely to present with co-morbidities at baseline such as left main and three-vessel disease, and lower EF which led to longer median procedure times and greater median volume of contrast in the Impella arm. Despite these increased risk factors for kidney injury in the Impella arm, the authors found that just 5.2 percent of the Impella-supported patients developed AKI post-procedure, compared to 27.8 percent in the unsupported patients’ cohort.  Less than one percent of Impella-supported patients required hemodialysis following the intervention, compared with 6.1 percent of unsupported patients; suggesting that patients who did not receive Impella were six times more likely to need dialysis.  The mean length of stay was also longer in the unsupported group. “A substantial number of high-risk PCI patients have both severely reduced left ventricular function and underlying kidney disease2, and during their procedure, these patients are exposed to high levels of contrast dye, which further compromises kidney function,” said Dr. Michael P. Flaherty, Associate Professor of Medicine and Physiology at University of Louisville School of Medicine; Primary Investigator and first and senior author. “We found that, despite severely reduced ejection fractions and baseline chronic kidney disease (CKD), Impella-supported patients were six times less likely to develop acute kidney injury, underscoring the importance of Impella as part of a renal protective strategy during high-risk PCI.” “We believe that kidney injury resulting from episodic decrease in flow during high-risk PCI can be reduced with Impella support and that stagnation of contrast in the renal tubules may be minimized,” continued Dr. Flaherty. “The use of Impella, then, is especially important as more patients undergo complete revascularization rather than staged procedures3, ostensibly improving periprocedural kidney blood flow and reducing the toxic effects of contrast dye despite low ejection fraction, baseline renal insufficiency and longer procedure times.” “Above and beyond the well-known value of cardiac protection, these data show Protected PCI with Impella may also help prevent renal damage which may require dialysis or other costly treatments,” said Dr. Seth Bilazarian, MD, Chief Medical Officer for Abiomed. “This is an important finding, because it may allow interventionalists treating high-risk patients to perform more complete revascularization in those with multi-vessel coronary disease. We can potentially reduce the risks and costs associated with multiple PCI procedures performed in stages, which is how many high-risk patients are still treated today.” _______________________
1.  Flaherty MP, Pant S, Patel SV, et al. Hemodynamic Support with a Micro-Axial Percutaneous Left Ventricular Assist Device (Impella®) Protects Against Acute Kidney Injury in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circ Res. 2017 Jan 10. 2.  O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012 Oct 2;126(14):1717-27. 3.  Watkins S, Oldroyd KG, Preda I, et al. Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study. EuroIntervention. 2015 Apr;10(12):1402-8. ABOUT IMPELLA The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP® are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP®, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com. The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S. and in certain foreign countries. Impella 2.5, Impella 5.0, and Recovering hearts. Saving lives. are trademarks of Abiomed, Inc. ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. FORWARD-LOOKING STATEMENTS This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact: 

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
[email protected]

Ingrid Goldberg
Director, Investor Relations
978-646-1590
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 121.29
ABMD's PE Ratio is ranked lower than
92% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. ABMD: 121.29 )
Ranked among companies with meaningful PE Ratio only.
ABMD' s PE Ratio Range Over the Past 10 Years
Min: 22.02  Med: 101.4 Max: 615.5
Current: 121.29
22.02
615.5
PE Ratio without NRI 121.29
ABMD's PE Ratio without NRI is ranked lower than
92% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. ABMD: 121.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.02  Med: 101.4 Max: 615.5
Current: 121.29
22.02
615.5
Price-to-Owner-Earnings 91.29
ABMD's Price-to-Owner-Earnings is ranked lower than
86% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. ABMD: 91.29 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 44.38  Med: 100.48 Max: 201.19
Current: 91.29
44.38
201.19
PB Ratio 13.52
ABMD's PB Ratio is ranked lower than
92% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. ABMD: 13.52 )
Ranked among companies with meaningful PB Ratio only.
ABMD' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.72 Max: 14.18
Current: 13.52
1.58
14.18
PS Ratio 14.03
ABMD's PS Ratio is ranked lower than
88% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ABMD: 14.03 )
Ranked among companies with meaningful PS Ratio only.
ABMD' s PS Ratio Range Over the Past 10 Years
Min: 2.36  Med: 6.48 Max: 17.6
Current: 14.03
2.36
17.6
Price-to-Free-Cash-Flow 84.83
ABMD's Price-to-Free-Cash-Flow is ranked lower than
90% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. ABMD: 84.83 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.85  Med: 62.16 Max: 665.41
Current: 84.83
22.85
665.41
Price-to-Operating-Cash-Flow 58.02
ABMD's Price-to-Operating-Cash-Flow is ranked lower than
89% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. ABMD: 58.02 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.12  Med: 52.98 Max: 430.93
Current: 58.02
21.12
430.93
EV-to-EBIT 67.13
ABMD's EV-to-EBIT is ranked lower than
90% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. ABMD: 67.13 )
Ranked among companies with meaningful EV-to-EBIT only.
ABMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -305.5  Med: -7.7 Max: 599.9
Current: 67.13
-305.5
599.9
EV-to-EBITDA 62.79
ABMD's EV-to-EBITDA is ranked lower than
90% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. ABMD: 62.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.6  Med: -5.1 Max: 727.3
Current: 62.79
-397.6
727.3
Shiller PE Ratio 960.87
ABMD's Shiller PE Ratio is ranked lower than
98% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. ABMD: 960.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 749.71  Med: 1571.57 Max: 12369
Current: 960.87
749.71
12369
Current Ratio 5.66
ABMD's Current Ratio is ranked higher than
86% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. ABMD: 5.66 )
Ranked among companies with meaningful Current Ratio only.
ABMD' s Current Ratio Range Over the Past 10 Years
Min: 2.43  Med: 6.73 Max: 32.71
Current: 5.66
2.43
32.71
Quick Ratio 5.12
ABMD's Quick Ratio is ranked higher than
87% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ABMD: 5.12 )
Ranked among companies with meaningful Quick Ratio only.
ABMD' s Quick Ratio Range Over the Past 10 Years
Min: 2  Med: 5.7 Max: 31.29
Current: 5.12
2
31.29
Days Inventory 160.21
ABMD's Days Inventory is ranked lower than
62% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. ABMD: 160.21 )
Ranked among companies with meaningful Days Inventory only.
ABMD' s Days Inventory Range Over the Past 10 Years
Min: 138.81  Med: 154.05 Max: 314.91
Current: 160.21
138.81
314.91
Days Sales Outstanding 44.18
ABMD's Days Sales Outstanding is ranked higher than
83% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. ABMD: 44.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.18  Med: 56.52 Max: 87.14
Current: 44.18
44.18
87.14
Days Payable 80.47
ABMD's Days Payable is ranked higher than
63% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ABMD: 80.47 )
Ranked among companies with meaningful Days Payable only.
ABMD' s Days Payable Range Over the Past 10 Years
Min: 60.98  Med: 97.03 Max: 218.64
Current: 80.47
60.98
218.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.30
ABMD's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ABMD: -3.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.2  Med: -5.3 Max: -0.8
Current: -3.3
-15.2
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 36.03
ABMD's Price-to-Net-Cash is ranked lower than
71% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. ABMD: 36.03 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.29  Med: 10.91 Max: 73.96
Current: 36.03
1.29
73.96
Price-to-Net-Current-Asset-Value 22.66
ABMD's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. ABMD: 22.66 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.08  Med: 7.11 Max: 28.5
Current: 22.66
1.08
28.5
Price-to-Tangible-Book 15.17
ABMD's Price-to-Tangible-Book is ranked lower than
87% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. ABMD: 15.17 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 5.43 Max: 16.32
Current: 15.17
1
16.32
Price-to-Intrinsic-Value-Projected-FCF 7.05
ABMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
84% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. ABMD: 7.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.39  Med: 7.6 Max: 163.8
Current: 7.05
4.39
163.8
Price-to-Median-PS-Value 2.17
ABMD's Price-to-Median-PS-Value is ranked lower than
90% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ABMD: 2.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.99 Max: 6.49
Current: 2.17
0.35
6.49
Price-to-Peter-Lynch-Fair-Value 4.86
ABMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
84% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.61 vs. ABMD: 4.86 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.31  Med: 4.21 Max: 35.22
Current: 4.86
2.31
35.22
Price-to-Graham-Number 9.06
ABMD's Price-to-Graham-Number is ranked lower than
93% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. ABMD: 9.06 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ABMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.99  Med: 6.1 Max: 15.52
Current: 9.06
2.99
15.52
Earnings Yield (Greenblatt) % 1.47
ABMD's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ABMD: 1.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 1.4 Max: 3.7
Current: 1.47
0.2
3.7
Forward Rate of Return (Yacktman) % 76.72
ABMD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. ABMD: 76.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -40.8  Med: 0.2 Max: 76.9
Current: 76.72
-40.8
76.9

More Statistics

Revenue (TTM) (Mil) $414.6
EPS (TTM) $ 1.07
Beta-0.47
Short Percentage of Float4.97%
52-Week Range $92.03 - 132.95
Shares Outstanding (Mil)43.54

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 454 627
EPS ($) 1.15 2.06
EPS without NRI ($) 1.15 2.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification Apr 13 2017 
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts Mar 30 2017 
7 Stocks That Are Outperforming the Market Mar 22 2017 
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance Mar 19 2017 
Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session Mar 16 2017 
New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneo Mar 09 2017 
6 Stocks That Beat the Market Oct 05 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Panic-Proofing the Small Investor Aug 26 2015 
Impressive Numbers That Matter: Abiomed Inc (ABMD), Freescale Semiconductor Ltd (FSL), Apple Inc (AA Jan 28 2015 

More From Other Websites
3 Top Stocks to Buy With Your Tax Refund Apr 22 2017
Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification Apr 13 2017
ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern Apr 10 2017
Abiomed unveils expanded Danvers HQ as headcount soars Mar 30 2017
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts Mar 30 2017
First-Ever Presentation on Abiomed's Impella® Quality (IQ) Assurance Program and Importance of... Mar 21 2017
Has Masimo Become Too Expensive to Hold? Mar 20 2017
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of... Mar 19 2017
Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session... Mar 16 2017
ABIOMED Impella Heart Pump Reduces Kidney Injury during PCI Mar 13 2017
New Study Finds Abiomed Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous... Mar 09 2017
ABIOMED (ABMD) Up 10.4% Since Earnings Report: Can It Continue? Feb 28 2017
3 Most Wildly Overvalued Stocks in Healthcare Feb 24 2017
Abiomed Surpasses 50,000 Impella® Patients Treated in the United States Feb 23 2017
These 3 Stocks Would Have Tripled Your Money Over the Last 3 Years Feb 21 2017
Abiomed Celebrates 2017 American Heart Month Feb 21 2017
ABIOMED, Inc. breached its 50 day moving average in a Bullish Manner : ABMD-US : February 17, 2017 Feb 17 2017
ETFs with exposure to ABIOMED, Inc. : February 14, 2017 Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)